Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of ...

Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

The thyroid is a small butterfly-shaped gland situated at the base of the neck. Despite its modest size, it exerts an ...

Chemical hair relaxers to straighten textured or curly hair, primarily used by Black women, may bring risks for several ...

Vertex Pharmaceuticals drops Q2 results tonight as a billion-dollar acquisition spree, a blockbuster pain drug launch, and a nephrology pipeline on the FDA's fast track collide with the first EPS ...

Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a ...

Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the ...

The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.

Gut microbiome-derived metabolites may influence stress-related mental disorders through neural, immune, endocrine, and epigenetic pathways. Evidence is strongest for depression and preclinical models ...

Scientists are uncovering a complex communication network linking the skin, immune system, and brain—one that could transform how chronic skin disease and mental health are treated.